Document Detail


Blood biomarkers for uveal melanoma.
MedLine Citation:
PMID:  22335584     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Uveal melanoma disseminates hematogenously, and blood biomarkers may be useful for prognosis and for monitoring disease progression. Melanoma-associated, metastatic and immune factors have been measured in the blood of patients with uveal melanoma, as have circulating melanoma cells. Most of the biomarkers were derived from studies in cutaneous melanoma. For various biological and/or technical reasons, these assessments have not demonstrated the accuracy required for effective prognostic or monitoring assays. Advances in uveal melanoma genomics and proteomics have generated many candidate biomarkers that are potentially measurable in blood. Measuring circulating nucleic acids may also be possible. Improvements in molecular profiling techniques that accurately predict metastatic risk in uveal melanoma patients should facilitate biomarker discovery and aid implementation in clinical testing. The stage is set to translate the advances made in understanding the molecular characteristics of uveal melanoma in order to identify and test clinically useful blood biomarkers of tumor dissemination and/or progression.
Authors:
Pierre L Triozzi; Arun D Singh
Related Documents :
7954574 - Strut interlocking of titanium greenfield vena cava filters and its effect on clot capt...
8459694 - A feasibility study of a filtration type autotransfusion device.
2296874 - Stable angina pectoris and controlled ischemia: what causes the abnormalities in whole ...
21180794 - Use of graduated syringes for measuring salivary flow rate: a pilot study.
11691614 - Morphometric characterization of the airway and vascular systems of the lung of the dom...
1259004 - Effects of time on volume and distribution of coronary collateral flow.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Future oncology (London, England)     Volume:  8     ISSN:  1744-8301     ISO Abbreviation:  Future Oncol     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-02-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101256629     Medline TA:  Future Oncol     Country:  England    
Other Details:
Languages:  eng     Pagination:  205-15     Citation Subset:  IM    
Affiliation:
Taussig Cancer Center, Cleveland, OH, USA. triozzp@ccf.org.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Advances in sentinel lymph node mapping for patients with melanoma.
Next Document:  Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone.